Could cannabinoids help fight COVID-19? A review of anti-inflammatory and antiviral evidence

A narrative review found that cannabinoids, particularly CBD and cannabigerolic acid, have anti-inflammatory and antiviral properties that could theoretically help with COVID-19, but clinical evidence is lacking.

Janecki, Marcin et al.·International journal of molecular sciences·2022·Preliminary EvidenceNarrative Review
RTHC-03930Narrative ReviewPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Cannabinoids interact with multiple receptors (GPR55, TRPV1, PPARs, 5-HT1A, adenosine, glycine) beyond CB1/CB2 to produce anti-inflammatory and antiviral effects. Since SARS-CoV-2 triggers excessive immune response and inflammatory cascades, cannabinoids' ability to regulate these processes suggests theoretical potential for COVID-19 treatment. Secondary cannabinoids like cannabigerolic acid (CBGA) and terpenes also showed anti-inflammatory and antiviral potential.

Key Numbers

Multiple receptor systems identified: CB1, CB2, GPR55, TRPV1, PPARs, 5-HT1A, adenosine, and glycine receptors. CBD and CBGA highlighted as most promising compounds.

How They Did This

Narrative review of literature from PubMed, Scopus, and Web of Science on cannabinoid anti-inflammatory and antiviral mechanisms potentially relevant to COVID-19.

Why This Research Matters

During the pandemic, many claims circulated about cannabis and COVID-19. This review consolidates what is actually known about the biological mechanisms while making clear that clinical evidence is absent.

The Bigger Picture

The review highlights the entourage effect, noting that secondary cannabinoids and terpenes may contribute to anti-inflammatory properties, challenging the focus on CBD and THC alone.

What This Study Doesn't Tell Us

No clinical trial data for cannabinoids in COVID-19 patients. Evidence based entirely on in vitro studies, preclinical models, and theoretical mechanisms. Anti-inflammatory effects in a lab do not guarantee clinical benefit.

Questions This Raises

  • ?Will clinical trials of cannabinoids for COVID-19 ever be conducted?
  • ?Could cannabinoid anti-inflammatory mechanisms be useful for other viral infections beyond COVID-19?

Trust & Context

Key Stat:
Multiple receptor pathways beyond CB1/CB2 contribute to anti-inflammatory effects
Evidence Grade:
Narrative review based on preclinical and in vitro evidence without any clinical trial data for the COVID-19 application.
Study Age:
Published in 2022.
Original Title:
Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.
Published In:
International journal of molecular sciences, 23(8) (2022)
Database ID:
RTHC-03930

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can cannabis help with COVID-19?

Cannabinoids have demonstrated anti-inflammatory and antiviral properties in lab studies, but no clinical trials have tested whether they actually help COVID-19 patients. The theoretical potential has not been validated in practice.

Which cannabinoids might fight viruses?

The review highlighted CBD and cannabigerolic acid (CBGA) as having the most promising anti-inflammatory and antiviral profiles, acting through multiple receptor systems beyond the traditional CB1 and CB2 cannabinoid receptors.

Read More on RethinkTHC

Cite This Study

RTHC-03930·https://rethinkthc.com/research/RTHC-03930

APA

Janecki, Marcin; Graczyk, Michał; Lewandowska, Agata Anna; Pawlak, Łukasz. (2022). Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.. International journal of molecular sciences, 23(8). https://doi.org/10.3390/ijms23084170

MLA

Janecki, Marcin, et al. "Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.." International journal of molecular sciences, 2022. https://doi.org/10.3390/ijms23084170

RethinkTHC

RethinkTHC Research Database. "Anti-Inflammatory and Antiviral Effects of Cannabinoids in I..." RTHC-03930. Retrieved from https://rethinkthc.com/research/janecki-2022-antiinflammatory-and-antiviral-effects

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.